Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the 8 Best Genomics Stocks to Buy According to Analysts.

On June 9, Truist analyst Gregory Renza raised Nurix Therapeutics, Inc. (NASDAQ:NRIX)’ price target to $32 from $30. The firm maintained a “Buy” rating on the shares. The analyst called the company’s partnership with Roche “strategically sensible.” It also cited a 50:50 US profit-share structure for bexdeg as justifiable, given potential execution gains in chronic lymphocytic leukemia and development into I&I and neurology. Truist added that the deal validates bexdeg’s broader clinical potential while strengthening Nurix’s balance sheet.

On June 8, Reuters reported that Roche entered an exclusive licensing and partnership agreement with Nurix Therapeutics, Inc. (NASDAQ:NRIX) worth up to $2.3 billion. The firm will receive $700 million upfront and milestone payments with development, regulatory, and sales targets. Roche said the deal centers on blood cancer drug bexobrutideg, with Phase III trials planned for the summer and potential launch around 2030. Deputy Chief Medical Officer Stefan Frings outlined the timeline, and Levi Garraway said the drug “could represent a major leap forward.”

Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical business. It finds, develops, and commercializes innovative small molecules and antibody therapies based on cellular protein modification as a unique treatment method for cancer, inflammatory disorders, and other challenging diseases.

While we acknowledge the risk and potential of NRIX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NRIX and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1